...
首页> 外文期刊>International Journal of Ayurvedic Medicine >Randomized Clinical Trial to Evaluate the Efficacy of Ashtamangal Ghrita Oral and Nasya in the Management of Cerebral Palsy
【24h】

Randomized Clinical Trial to Evaluate the Efficacy of Ashtamangal Ghrita Oral and Nasya in the Management of Cerebral Palsy

机译:随机临床试验评估Ashtamangal Ghrita口服和纳西亚在脑瘫管理中的疗效

获取原文
           

摘要

Background: Cerebral palsy is one of the most common childhood disabilities, which hinder the development of a child, causing extensive suffering to affected children and their families. According to world health organization about 10% of population have some form of disabilities. Cerebral Palsy can be compared with Vatavyadhi(neurological disorder) manifested in various form like sarvangavata (quadri-plegia), pakshaghata (hemiparesis), ekangavata(monoplegia), pangu and khanja (motor disorder), kampavata,? jadatva (mental retadation), mukatva (dumbness) etc. Objective: To evaluate the efficacy of Ashtamangal ghrita, in the form of oral medication and as nasya in the management of cerebral palsy. Material and Methods: Total 24 Children with physical and mental developmental disabilities of of age group 01 to 10 years of either sex were randomly divided into two groups, group A received Ashtamangal ghrita (orally) - 1 ml/kg body weight in two divided doses for 3 months and Group B received Pratimarsh Nasya with Ashtamangal ghrita – 2 drops in each nostril 2 times a day for 3 months. Assessments were done on the basis of 5 point grading score of Clinical symptoms of Cerebral Palsy as per standard classification scale for CP, i.e, motor functions were assessed on the basis of CDC Grading Scale for Motor milestones and Teacher’s drooling test. Follow up visit was on every 15th day. Result: Overall effect of therapy shows that there was 34.79% improvement in group A & 37.74% improvement in group B. Results were slightly superior in group B than group A in most of the parameters. Although intergroup comparison of both groups was not-significant or there were no differences in both groups statistically. Group A was slightly superior than group B in following parameters –Head holding, sitting, teacher drooling scale and spasticity. In all the other parameters group B was slightly superior. Conclusion: Clinical efficacy of?both?Ashtamangal ghrita orally and?as nasya on various parameters of Cerebral Palsy showed that both were effective, safe and comparable.
机译:背景:脑瘫是最常见的童年残疾之一,阻碍了一个孩子的发展,导致受影响的儿童及其家人造成广泛的痛苦。根据世界卫生组织,约有10%的人口有某种形式的残疾。脑瘫可以与Vatavyadhi(神经疾病)相比,以各种形式表现为Sarvangavata(Quadri-Plegia),Pakshaghata(夸粒),ekangavata(Monoplegia),Pangu和Khanja(Motor Dissicate),Kampavata,? Jadatva(心理回归),Mukatva(愚蠢)等目标:评估Ashtamangal Ghrita,以口腔用药的形式和纳西亚的疗效评估脑瘫。材料和方法:24例具有年龄组的身体和精神发育障碍的儿童01至10年的性别无论是随机分为两组,A次接受Ashtamangal GhRita(口服) - 1ml / kg体重两分液3个月,B组接受了普拉蒂玛斯·纳西亚与Ashtamangal Ghrita - 每天2次滴2次,每天3个月。根据CP的标准分类规模,根据CP,即在电动机里程碑和教师流口腔测试的基础上评估电机功能,根据标准分类规模进行评估。随访时间每隔15天。结果:疗法的总体效果表明,B组A&37.74%的改善34.79%。在大部分参数中,B组的结果略有优异。虽然两组的依法群比较不显着,但两组统计学都没有差异。 A组比B略有优于B组,在持有,坐着,老师流口尺和痉挛中。在所有其他参数中,B组略有优越。结论:临床疗效?两者兼何时·什antamangal,口服?作为鼻腔的鼻腔,脑瘫的各种参数表明,两者都有效,安全和可比。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号